Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Helen Shaw
Observed name:
H Shaw
Institution:
Proveca (United Kingdom)
Observed institution:
Proveca (United Kingdom)
ORCID:
0000-0001-7660-3930
Observed ORCID:
0000-0001-7660-3930
OpenAlex ID:
A5035457332
Glycopyrronium 320 μg/ mL in children and adolescents with severe sialorrhoea and neurodisabilities: A randomized, double‐blind, placebo‐controlled trial
2024
·
Pierre Fayoux
, Mickael Dinomais
, et al.
·
Developmental Medicine & Child Neurology
·
11
PDF
Randomised, double-blind, placebo-controlled trial of glycopyrronium in children and adolescents with severe sialorrhoea and neurodisabilities: protocol of the SALIVA trial
2023
·
Pierre Fayoux
, Mickael Dinomais
, et al.
·
BMJ Paediatrics Open
·
4
PDF
Glycopyrronium 320 μg/ mL in children and adolescents with severe sialorrhoea and neurodisabilities: An open‐label study extension of the SALIVA trial
2025
·
Pierre Fayoux
, Mickael Dinomais
, et al.
·
Developmental Medicine & Child Neurology
·
2
PDF
P27 The accuracy of tablet splitting to provide appropriate paediatric enalapril doses
2023
·
Amy Conquest
, Matt Ames
, et al.
·
Archives of Disease in Childhood
PDF
Budget Impact Analysis of Oral Glycopyrronium Bromide (Sialanar™) For The Symptomatic Treatment of Severe Sialorrhoea (DROOLING) In The UK Setting
2017
·
S Langham
, A Wright
, et al.
·
Value in Health
Show more works
View as search
Works count:
5
Citation count:
17
H-index:
2
I10-index:
1
Year
Topic
Type